RefleXion Medical
RefleXion Medical is a private Hayward, California-based oncology device company that develops and sells the RefleXion X1 and SCINTIC biology-guided radiotherapy systems, using PET-CT radiotracers to deliver real-time, biologically guided radiation to hospitals and cancer treatment centers.
- Company typePrivate
- Founded2009
- HeadquartersHayward, United States
- Headcount251–500
- GTM typeB2B
- OfferingHardware or Manufacturing
What RefleXion Medical does
RefleXion Medical is a private therapeutic oncology company founded in 2009 and headquartered in Hayward, California, that develops and commercializes biologically-guided radiotherapy (BgRT) systems for cancer treatment. Its flagship RefleXion X1 platform and the SCINTIC biology-guided radiotherapy system use PET-CT radiotracers to guide radiation delivery to tumors in real time based on biological signals, rather than relying solely on pre-treatment anatomical imaging. This architecture enables the system to track and treat all visible cancer sites simultaneously, including late-stage and metastatic disease, and is positioned to address indications in lung, prostate, and kidney cancers following FDA Breakthrough Device Designation for lung tumors and FDA 510(k) clearance of the SCINTIC system in February 2023.
The company's revenue model is anchored in enterprise capital equipment sales of the RefleXion X1 platform to hospitals and cancer treatment centers through a direct field sales motion; pricing is not publicly disclosed. The firm is also developing a radiopharmaceutical program intended to expand treatment options for metastatic cancer, potentially opening a companion diagnostic or therapeutic channel tied to the BgRT platform. RefleXion Medical has raised cumulative equity and debt funding exceeding $575 million across multiple rounds since 2014, with strategic participation from Pfizer Ventures and Johnson & Johnson Innovation, and is led by President and CEO Todd Powell alongside founder and CTO Samuel Mazin.
RefleXion Medical firmographics
Firmographics- Name
- RefleXion Medical
- Legal name
- RefleXion Medical
- Website
- http://www.reflexion.com
- Company type
- Private
- Founded year
- 2009
- Operating status
- Operating
- Headcount range
- 251–500 employees
- Short description
- RefleXion Medical is a private Hayward, California-based oncology device company that develops and sells the RefleXion X1 and SCINTIC biology-guided radiotherapy systems, using PET-CT radiotracers to deliver real-time, biologically guided radiation to hospitals and cancer treatment centers.
- Ownership category
- akta.pro rank
RefleXion Medical industry classification
Industry- Product category
- Radiation Therapy Equipment
- NAICS
- Irradiation Apparatus Manufacturing (334517)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Radiation Oncology (HLAKAFAC)
Keywords
Where RefleXion Medical is headquartered
LocationHeadquarters
- HQ city
- Hayward
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
RefleXion Medical business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations
Revenue model
- Radiotherapy Equipment Sales: RefleXion Medical generates revenue through the sale of its RefleXion X1 radiotherapy platform, a medical device system used in cancer treatment at hospitals and treatment centers. The company also supports commercial expansion efforts and development of new clinical indications.
- Radiopharmaceutical Program: The company is growing its radiopharmaceutical program to expand treatment options for metastatic cancer, suggesting future revenue potential from companion diagnostics or therapeutic radiopharmaceuticals used with the BgRT platform.
Go-to-market motion2 records
Distribution channels1 record
Marketing channels3 records
RefleXion Medical product offering
Product offeringCore offering
RefleXion Medical develops and commercializes the RefleXion X1 platform, an FDA-cleared radiotherapy system that delivers biology-guided radiotherapy (BgRT) using PET-CT radiotracers to track tumors and guide radiation in real time. The platform is intended for hospitals and cancer treatment centers to treat multiple visible cancer sites, including metastatic disease, lung tumors, and advanced prostate and kidney cancers.
Product overview
RefleXion Medical is a therapeutic oncology company offering a unified platform approach centered on two key products: the RefleXion X1 platform and the SCINTIC biology-guided radiotherapy system. The SCINTIC system, which received FDA approval in February 2023, is the commercial implementation of the company's proprietary BgRT (Biologically Guided Radiotherapy) technology. This technology uses PET-CT radiotracers to guide radiotherapy delivery in real-time, enabling treatment of all visible cancer sites including late-stage metastatic disease, lung tumors, prostate cancer, and kidney cancers. The company is expanding its clinical indications to address advanced cancers.
Differentiator
Problem solved
Functional benefit
Products and services
- RefleXion X1 Platform
Quantifiable outcome
- FDA breakthrough device designation for lung tumor treatment
- +1 more outcomes
Companies that use RefleXion Medical
Customer profileSegments2 records
Ideal customer profiles1 record
RefleXion Medical technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
RefleXion Medical partnerships and signals
Strategic signalScale indicators5 records
Recent moves6 records
Expansion highlights5 records
RefleXion Medical competitors and assessment
Company assessmentDirect peers
- Varian Medical Systems: Acquired by Siemens Healthineers in 2021, Varian is the global market leader in linear accelerators and radiation oncology treatment planning. It is the closest direct competitor to RefleXion, serving the same hospitals and radiation oncologists with conventional and adaptive radiotherapy systems.
- Elekta: Swedish-headquartered Elekta is the second major radiation oncology equipment vendor, competing head-to-head with Varian and RefleXion in linear accelerators, brachytherapy, and stereotactic radiosurgery. Same customer base (cancer centers and hospitals) and same enterprise capital sales motion.
- Accuray: Accuray manufactures the CyberKnife and TomoTherapy systems, competing in the radiation oncology capital equipment space. Targets similar hospital and freestanding cancer center customers, particularly for stereotactic and hypofractionated treatments where RefleXion also competes.
- Mevion Medical Systems: Mevion develops compact proton therapy systems for cancer treatment, competing in the same radiation oncology capital equipment category with a different modality. Comparable customer base of mid-sized hospitals seeking advanced radiotherapy technology.
Broad incumbents
- Siemens Healthineers: Parent of Varian and a major diagnostic imaging vendor. Competes broadly in oncology imaging and therapy including PET-CT scanners that pair with RefleXion's tracer workflow, as well as in conventional linacs through Varian.
- GE HealthCare: Major diagnostic imaging vendor including PET-CT scanners used in radiotracer-guided workflows. While not a direct radiotherapy competitor, it is an incumbent in the imaging ecosystem that hospitals must integrate RefleXion with.
- Philips: Healthcare technology incumbent in diagnostic imaging, treatment planning, and oncology informatics. Competes broadly with RefleXion through imaging and treatment planning software used alongside radiation therapy delivery.
Emerging players
- Lantheus Holdings: Lantheus is a leading radiopharmaceutical company producing diagnostic PET tracers (e.g., Pylarify for prostate cancer). Highly relevant as a potential partner or competitor in supplying the PET tracers that RefleXion's BgRT system depends on.
- Telix Pharmaceuticals: Telix develops and commercializes diagnostic and therapeutic radiopharmaceuticals, including Illuccix (PSMA-PET tracer for prostate cancer). Relevant as a potential radiotracer partner for BgRT applications in prostate cancer.
- Alpha Tau Medical: Alpha Tau is developing alpha-emitter radiation therapy for solid tumors. Comparable as an emerging radiotherapy modality company pursuing novel approaches to treat cancers that are difficult to address with conventional radiotherapy.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
RefleXion Medical social profiles
Digital presenceRefleXion Medical compliance and trust
Trust signalCompliance2 records
RefleXion Medical financial estimates
Financial estimateRevenue estimate
Valuation estimate
RefleXion Medical leadership team
Management profileNumber of profiles
Profiles9 records
RefleXion Medical funding detail
Funding detailFunding overview
Funding rounds11 records
Investors19 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
RefleXion Medical M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about RefleXion Medical
What does RefleXion Medical do?
RefleXion Medical develops and commercializes the RefleXion X1 platform, an FDA-cleared radiotherapy system that delivers biology-guided radiotherapy (BgRT) using PET-CT radiotracers to track tumors and guide radiation in real time. The platform is intended for hospitals and cancer treatment centers to treat multiple visible cancer sites, including metastatic disease, lung tumors, and advanced prostate and kidney cancers.
Is RefleXion Medical a public or private company?
RefleXion Medical is a private company. It is classified as venture growth investor backed and is currently operating.
When was RefleXion Medical founded?
RefleXion Medical was founded in 2009. It employs 251 to 500 people.
Where is RefleXion Medical based?
RefleXion Medical is headquartered in Hayward, United States, in the North America region.
How does RefleXion Medical make money?
Two revenue lines are on record. Radiotherapy Equipment Sales are the primary driver. The others are radiopharmaceutical Program.
Who are RefleXion Medical's main competitors?
Direct peers on record are Varian Medical Systems, Elekta, Accuray and Mevion Medical Systems. Broad incumbents are Siemens Healthineers, GE HealthCare and Philips. Emerging players are Lantheus Holdings, Telix Pharmaceuticals and Alpha Tau Medical.
Does RefleXion Medical have an API?
No public API is recorded for RefleXion Medical.
What industry is RefleXion Medical in?
RefleXion Medical's product category is Radiation Therapy Equipment. Its primary akta.pro industry code is HLAKAFAC, Radiation Oncology. Its NAICS code is 334517 and its SIC code is 3841.